Stem Cell, Drug Discovery, and Analytical Services
Our services help stem cell and drug discovery scientists around the world advance their preclinical and clinical research.
On the REPROCELL blog
Latest
Redefining Success in IBD Drug Discovery with Human Tissue Models
Redefining IBD drug discovery with a dual-pronged approach through human bioengineered and fresh tissue.
11 December 2024
Pharma AI is Changing Clinical Trials by Optimizing Patient Selection
AI is revolutionizing clinical trials by optimizing patient selection, improving trial outcomes, and accelerating the development of new drugs.
27 November 2024
Key Strategies Central Labs Use to Fast-Track Time to Market
Learn how central labs use automation, outsourcing, and AI to accelerate drug development, reduce costs, and improve clinical trial accuracy and efficiency.
18 November 2024
REPROCELL's Advanced Skin Tissue Engineering
Discover REPROCELL's pioneering 3D skin tissue engineering, enhancing drug development and skincare research with accurate and robust human skin models.
31 October 2024
Plasma or Serum? – You Decide.
Discover the key differences between plasma and serum, their collection methods, and their impact on clinical and experimental outcomes.
17 October 2024
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Come meet us on 20-23 January, 2025 at Dallas, TX. Venue: the Kay Bailey Hutchison Convention Center Dallas.
Corporate News
Qkine Ltd., and REPROCELL Inc., have partnered to globally distribute high-quality proteins such as growth factors and cytokines manufactured by Qkine.
10 January 2025
PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models
New study by Prof Stefan Przyborski at Durham University enhances drug testing models with stromal support in bioengineered human intestinal tissue.
13 November 2024
PRESS RELEASE: Bioserve India Launches Advanced Stem Cell Products
Discover Bioserve India's advanced stem cell products, supporting innovation in research and drug development.
22 July 2024